Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK002 in antihistamine-resistant chronic urticaria
NCT03436797Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- Jan 2018
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of lirentelimab in chronic urticaria (CU), sponsored by Allakos Inc.. Started Jan 2018; status: completed.
02
Drugs
lirentelimab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT03436797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436797.